Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Calvez

Showing results (251-260 of 329) with videos related to

Pageof 33
Sort By:
Open Forum Infectious Diseases|May 25, 2019
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow LevelsSidonie Lambert-Niclot, Anders Boyd, Djeneba Fofana, et al.
The Lancet. HIV|July 29, 2022
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort studyBirgit Schramm, Elvis Temfack, Diane Descamps, et al.
Scandinavian Journal of Infectious Diseases|March 13, 2010
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patientsFabienne Caby, Nadia Valin, Anne Genevieve Marcelin, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|October 22, 2024
Dynamics of SARS-CoV-2 variants in West Africa: Insights into genomic surveillance in resource-constrained settingsJosue Togo, Anou Moise Somboro, Oumar Dolo, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2021
Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoirBasma Abdi, Sidonie Lambert-Niclot, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2025
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stableCathia Soulie, Rachid Agher, Antoine Fauchois, et al.
Journal of Global Antimicrobial Resistance|August 10, 2022
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES studyMaria Mercedes Santoro, Daniele Armenia, Elisa Teyssou, et al.
The Journal of Antimicrobial Chemotherapy|January 9, 2025
Major role of dolutegravir in the emergence of the S147G integrase resistance mutationMarc Wirden, Basma Abdi, Sidonie Lambert-Niclot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapyBenjamin Ribba, Gentian Kaloshi, Mathieu Peyre, et al.
The Journal of Infectious Diseases|April 14, 2020
New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologiesAude Jary, Valentin Leducq, Nathalie Desire, et al.
Pageof 33

Showing results (251-260 of 329) with videos related to

Sort By:
Pageof 33
Open Forum Infectious Diseases|May 25, 2019
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow LevelsSidonie Lambert-Niclot, Anders Boyd, Djeneba Fofana, et al.
The Lancet. HIV|July 29, 2022
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort studyBirgit Schramm, Elvis Temfack, Diane Descamps, et al.
Scandinavian Journal of Infectious Diseases|March 13, 2010
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patientsFabienne Caby, Nadia Valin, Anne Genevieve Marcelin, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|October 22, 2024
Dynamics of SARS-CoV-2 variants in West Africa: Insights into genomic surveillance in resource-constrained settingsJosue Togo, Anou Moise Somboro, Oumar Dolo, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2021
Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoirBasma Abdi, Sidonie Lambert-Niclot, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2025
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stableCathia Soulie, Rachid Agher, Antoine Fauchois, et al.
Journal of Global Antimicrobial Resistance|August 10, 2022
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES studyMaria Mercedes Santoro, Daniele Armenia, Elisa Teyssou, et al.
The Journal of Antimicrobial Chemotherapy|January 9, 2025
Major role of dolutegravir in the emergence of the S147G integrase resistance mutationMarc Wirden, Basma Abdi, Sidonie Lambert-Niclot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapyBenjamin Ribba, Gentian Kaloshi, Mathieu Peyre, et al.
The Journal of Infectious Diseases|April 14, 2020
New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologiesAude Jary, Valentin Leducq, Nathalie Desire, et al.
Pageof 33